Khurana, Rakesh, Joel Podolny, and Jaan Margus Elias. "Veridian: Putting a Value on Values." Harvard Business School Case 406-028, February 2006. (Revised October 2006.) ...
Viridian Therapeutics ( (VRDN)) has issued an update. Viridian Therapeutics, a biotech company, highlights its recent advancements in treating thyroid eye disease (TED) and FcRn inhibitor ...
But when multiple insiders are buying like they did in the case of Viridian Therapeutics, Inc. (NASDAQ:VRDN), that sends out a positive message to the company's shareholders. While we would never ...
(“Viridian”), constituting its Qualifying Transaction (as defined by Policy 2.4 ... Forward-looking information includes, but is not limited to, information regarding: (i) the business plans and ...
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases ...